BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leong P, Macdonald MI, Ko BS, Bardin PG. Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge. Medical Journal of Australia 2019;210:417-23. [DOI: 10.5694/mja2.50120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Qiu Y, Wang Y, Shen N, Wang Q, Chai L, Wang J, Zhang Q, Chen Y, Liu J, Li D, Chen H, Li M. Nomograms for Predicting Coexisting Cardiovascular Disease and Prognosis in Chronic Obstructive Pulmonary Disease: A Study Based on NHANES Data. Can Respir J 2022;2022:5618376. [PMID: 35721788 DOI: 10.1155/2022/5618376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Fang H, Zhang M, Zhao C, Yao X, Wang H, Xia H, Yu M. Characteristics of length of stay and cardiovascular pharmacotherapy advice among chronic obstructive pulmonary disease patients. Sci Prog 2021;104:368504211066003. [PMID: 34907809 DOI: 10.1177/00368504211066003] [Reference Citation Analysis]
3 Wang Y, Kuang X, Yin Y, Han N, Chang L, Wang H, Hou Y, Li H, Li Z, Liu Y, Hao Y, Wei Y, Wang X, Jia Z. Tongxinluo prevents chronic obstructive pulmonary disease complicated with atherosclerosis by inhibiting ferroptosis and protecting against pulmonary microvascular barrier dysfunction. Biomed Pharmacother 2021;145:112367. [PMID: 34740097 DOI: 10.1016/j.biopha.2021.112367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Leong P, Osadnik CR, King PT, MacDonald MI, Ko BS, Lau KK, Joosten SA, Kathriachchige G, Chua A, Hamza K, Kuganesan A, Troupis JM, Bardin PG. Right ventricular end-diastolic volume and outcomes in exacerbations of COPD. Respirology 2021. [PMID: 34693587 DOI: 10.1111/resp.14170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Yeoh SE, Dewan P, Serenelli M, Ferreira JP, Pitt B, Swedberg K, van Veldhuisen DJ, Zannad F, Jhund PS, McMurray JJV. Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. Eur J Heart Fail 2021. [PMID: 34536265 DOI: 10.1002/ejhf.2350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Shi Y, Zhang J, Huang Y. Prediction of cardiovascular risk in patients with chronic obstructive pulmonary disease: a study of the National Health and Nutrition Examination Survey database. BMC Cardiovasc Disord 2021;21:417. [PMID: 34470611 DOI: 10.1186/s12872-021-02225-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Reiffel JA. When two is not better than one: the amalgamation of atrial fibrillation and chronic obstructive pulmonary disease. Eur Heart J 2021:ehab366. [PMID: 34333594 DOI: 10.1093/eurheartj/ehab366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Martinez-Garcia MÁ, Faner R, Oscullo G, la Rosa-Carrillo D, Soler-Cataluña JJ, Ballester M, Muriel A, Agusti A. Chronic bronchial infection and incident cardiovascular events in chronic obstructive pulmonary disease patients: A long-term observational study. Respirology 2021;26:776-85. [PMID: 34002922 DOI: 10.1111/resp.14086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 MacDonald MI, Bardin PG. Contemporary Concise Review 2020: Chronic obstructive pulmonary disease. Respirology 2021;26:493-500. [PMID: 33749929 DOI: 10.1111/resp.14037] [Reference Citation Analysis]
10 Leong P, Bardin PG. The untreated treatable trait: Cardiovascular disease in COPD exacerbations. Respirology 2021;26:413-5. [PMID: 33751741 DOI: 10.1111/resp.14036] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Leong P, MacDonald MI, King PT, Osadnik CR, Ko BS, Landry SA, Hamza K, Kugenasan A, Troupis JM, Bardin PG. Treatable cardiac disease in hospitalised COPD exacerbations. ERJ Open Res 2021;7:00756-2020. [PMID: 34104641 DOI: 10.1183/23120541.00756-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Zucchi JW, Franco EAT, Schreck T, Castro E Silva MH, Migliorini SRDS, Garcia T, Mota GAF, de Morais BEB, Machado LHS, Batista ANR, de Paiva SAR, de Godoy I, Tanni SE. Different Clusters in Patients with Chronic Obstructive Pulmonary Disease (COPD): A Two-Center Study in Brazil. Int J Chron Obstruct Pulmon Dis 2020;15:2847-56. [PMID: 33192058 DOI: 10.2147/COPD.S268332] [Reference Citation Analysis]
13 Liao KM, Kuo LT, Lu HY. Increased risk of peripheral arterial occlusive diseases in patients with chronic obstructive pulmonary disease: a nationwide study in Taiwan. Int J Chron Obstruct Pulmon Dis 2019;14:1455-64. [PMID: 31308650 DOI: 10.2147/COPD.S202029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]